REPLIMUNE GROUP, INC. Other Noncash Expense
REPLIMUNE GROUP, INC. (REPL) reported Other Noncash Expense of $786.00 thousand for the 9-month period ending 2023-12-31, per its 10-Q filed 2024-02-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashExpense · last filed 2024-02-08
- REPLIMUNE GROUP, INC. other noncash expense for the quarter ending 2023-12-31 was $273.00K, a 16.17% increase year-over-year.
- REPLIMUNE GROUP, INC. other noncash expense for the quarter ending 2023-09-30 was $256.00K.
- REPLIMUNE GROUP, INC. other noncash expense for the quarter ending 2023-06-30 was $257.00K.
- REPLIMUNE GROUP, INC. other noncash expense for the quarter ending 2022-12-31 was $235.00K.
| Period end | Other Noncash Expense 3 month | Other Noncash Expense 6 month | Other Noncash Expense 9 month |
|---|---|---|---|
| 2023-12-31 | $273.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-08 | $529.00K derived: sum of 2 quarters · filed 2024-02-08 | $786.00K 10-Q · filed 2024-02-08 |
| 2023-09-30 | $256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-07 | $513.00K 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $257.00K 10-Q · filed 2023-08-03 | ||
| 2022-12-31 | $235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-08 | $235.00K derived: sum of 2 quarters · filed 2024-02-08 | $235.00K 10-Q · filed 2024-02-08 |
| 2022-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | ||
| 2021-12-31 | $0.00 10-Q · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |